康替唑胺治疗结核病的研究进展  

Research progress in the treatment of tuberculosis with contezolid

作　　者：王宇津 初乃惠[1] 聂文娟[1] Wang Yujin;Chu Naihui;Nie Wenjuan(The First Department of Tuberculosis,Beijing Chest Hospital,Capital Medical University,Beijing 101149,China)

机构地区：[1]首都医科大学附属北京胸科医院结核一科,北京101149

出　　处：《中国防痨杂志》2024年第11期1395-1399,共5页Chinese Journal of Antituberculosis

基　　金：北京市医院管理中心2023年度临床医学发展专项“扬帆3.0”项目(ZLRK202331)。

摘　　要：全球结核病防治形势不容乐观,发病率和病亡率居高不下,中国依然是全球结核病高负担国家之一。近年来,作为噁唑烷酮类药物的代表,利奈唑胺在耐药和重症结核病治疗中的应用日益广泛,因突出的抗菌疗效,其临床地位不断提升,但由于骨髓抑制、周围神经病变等不良反应的频繁发生,导致其在长疗程的结核病治疗中的应用受到了很大的限制。康替唑胺通过对利奈唑胺构效改造获得,其不良反应大大降低。近年来,越来越多的研究关注于康替唑胺在结核病治疗中的作用。本文阐述了康替唑胺治疗结核病的研究进展,以期为临床使用康替唑胺治疗结核病提供借鉴。The global situation of tuberculosis prevention and control is not optimistic,with high incidence rate and mortality.China is still one of the countries with high burden of tuberculosis in the world.In recent years,as the representative of oxazolidinones,linezolid has been increasingly widely used in the treatment of drug-resistant and severe tuberculosis.Due to its outstanding antibacterial effect,its clinical status has been continuously improved.However,due to the frequent occurrence of bone marrow suppression,peripheral neuropathy and other adverse reactions,its application in the long-term treatment of tuberculosis has been greatly limited.Contezolid is obtained by modifying the structure and activity of linezolid,greatly reducing its adverse reactions.In recent years,more and more studies have focused on the role of contezolid in the treatment of tuberculosis.In this paper,the research progress of contezolid in the treatment of tuberculosis was reviewed,with a view to providing reference for clinical use of contezolid in the treatment of tuberculosis.

关 键 词：结核 抗药性 抗菌药 恶唑烷酮类 综述文献(主题) 

分 类 号：R52[医药卫生—内科学]